Treatment for patients with cancer.

about

Antithrombotic therapy in patients with thrombocytopenic cancer: outcomes associated with reduced-dose, low-molecular-weight heparin during hospitalization.von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans.

P2860

Q33416407-5C983C0E-2E9B-457A-8C85-FDABAC96A2D6 Q40671371-4EB0A44A-E418-4EFB-A415-A7F208326BD0

P2860

Treatment for patients with cancer.

Item

http://www.wikidata.org/entity/Q44188629

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Treatment for patients with cancer.

@en

Treatment for patients with cancer.

@nl

type

Item

label

Treatment for patients with cancer.

@en

Treatment for patients with cancer.

@nl

prefLabel

Treatment for patients with cancer.

@en

Treatment for patients with cancer.

@nl

P1476

Treatment for patients with cancer.

@en

P2093

Andrew Nicolaides

http://www.w3.org/2001/XMLSchema#string

Cardiovascular Disease Educational and Research Trust

http://www.w3.org/2001/XMLSchema#string

European Venous Forum

http://www.w3.org/2001/XMLSchema#string

International Union of Angiology and Union Internationale du Phlebologie

http://www.w3.org/2001/XMLSchema#string

Jawed Fareed

http://www.w3.org/2001/XMLSchema#string

North American Thrombosis Forum

http://www.w3.org/2001/XMLSchema#string

Russell D Hull

http://www.w3.org/2001/XMLSchema#string

P2860

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer

A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency.

Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis.

Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis.

Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis.

Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials.

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials.

Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer.

Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism.

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.

P304

206-208

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1076029612474840R

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

278396895

http://www.w3.org/2001/XMLSchema#string

P698

23529494

http://www.w3.org/2001/XMLSchema#string

Treatment for patients with cancer.

about

P2860

P2860

Treatment for patients with cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698